Arcadia Science

Arcadia Science operates as a for-profit incubator, integrating a core research platform to advance therapeutic discovery. The company leverages evolutionary biology, studying life's diverse organisms and their adaptations, to predict and test novel therapeutics. It develops and openly shares computational tools, software pipelines, and research protocols, fostering a collaborative approach to scientific innovation that accelerates the translation of biological insights into practical applications.

The company was founded around mid-2021 by Seemay Chou (CEO), Prachee Avasthi (CSO), and Jed McCaleb. Their founding insight centered on the conviction that harnessing evolutionary principles can profoundly inform and accelerate drug development. This approach also seeks to establish a new paradigm for scientific endeavor, emphasizing open science and integrated research to address complex biological challenges.

Arcadia Science primarily serves researchers and its own incubated ventures, providing a robust platform for discovery and development. Its long-term vision is to function as an "invention factory," cultivating a scientist-centric entrepreneurial ecosystem. The company aims for financial self-sustainability, ultimately demonstrating that a science-first mindset can yield significant profitability and shape the future landscape of biological research and innovation.